Cite
HARVARD Citation
Zitomersky, N. et al. (n.d.). P-117 Combination Therapy with Immunomodulator and Infliximab is Associated with Higher Infliximab Trough Levels and Decreased Likelihood of Antibody Formation. Inflammatory bowel diseases. p. . [Online].